Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
This Framework Agreement is for the supply of medicines used in the treatment of Hepatitis C to NHSScotland. It includes both a treatment cost per medicine and a treatment spend cap.
| Supplier | Identifier | Award Value | Lots Won | Cross-References |
|---|---|---|---|---|
| AbbVie Ltd | 08004972 | - | 2 lots Treatment Cost per Medicine · Treatment Spend Cap | LOBBYIST Policy Connect Limited (15 quarters) Portland PR Limited (3 quarters) WA Communications Ltd (3 quarters) Incisive Health Ltd (1 quarter) Political Lobbying & Media Relations Limited (1 quarter) |
| Gilead Sciences Ltd | 02543818 | - | 2 lots Treatment Cost per Medicine · Treatment Spend Cap | LOBBYIST Ovid Consulting Ltd (4 quarters) Portland PR Limited (1 quarter) WA Communications Ltd (1 quarter) |
| Merck Sharp & Dohme UK Ltd | 00233687 | - | 1 lot Treatment Cost per Medicine | - |
This procurement was divided into 2 lots, each awarded separately.
| Lot | Value | Awarded To | Status |
|---|---|---|---|
| Lot 1 Treatment Cost per Medicine | £5,873,754 initial term | AbbVie Ltd Gilead Sciences Ltd Merck Sharp & Dohme UK Ltd | complete |
| Lot 2 Treatment Spend Cap | £5,873,754 initial term | AbbVie Ltd Gilead Sciences Ltd | complete |
Government spending data: These suppliers have received £437,289,091 in 1,056 payments (over £25k) from Department of Health and Social Care, Manchester University NHS Foundation Trust, UK Health Security Agency, The Christie NHS Foundation Trust, Plymouth Hospitals NHS Trust and 9 more public bodies (2018-02-28 to 2026-03-31).